Eli Lilly Sues Actavis To Block Generic ADHD Drug

Law360, New York (August 10, 2007, 12:00 AM EDT) -- Eli Lilly & Co. has filed a lawsuit against a U.S. subsidiary of Iceland-based Actavis, looking to stave off generic competition in the $509 million annual U.S. market for the attention-deficit hyperactivity disorder drug Strattera.

Eli Lilly filed the lawsuit Wednesday against sole defendant Actavis Elizabeth LLC in the U.S. District Court for the Southern District of Indiana, in connection with Actavis' filing of an Abbreviated New Drug Application seeking the U.S. Food and Drug Administration's approval for generic versions of Strattera.

At issue is U.S....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.